Lucy To
Lucy To was named Chief Financial Officer in August of 2024, bringing over 18 years of investment banking and strategic operational expertise to SAB to lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. Prior to joining SAB, she was a Managing Director in the Healthcare Investment Banking Group at Wells Fargo where she advised biopharmaceutical companies on financing and strategic transactions. Her career experience includes additional investment banking and operational experience at Deutsche Bank, Intercept Pharmaceuticals, Citigroup, and Cowen. Her transaction experience includes M&A, IPOs and other equity and debt financings in the healthcare sector with an aggregate transaction value in excess of $50 billion.